Literature DB >> 9610386

Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

M E Ganapathy1, W Huang, H Wang, V Ganapathy, F H Leibach.   

Abstract

Valacyclovir is a prodrug of the antiviral agent acyclovir and it does not contain a peptide bond in its structure. We studied the interaction of valacyclovir with the peptide transporters in the human intestinal cell line Caco-2 and the rat kidney proximal tubular cell line SKPT which differentially express peptide transporters PEPT1 and PEPT2. The results of the studies done with these cell lines were confirmed with the cloned peptide transporters human PEPT1 and rat PEPT2, expressed heterologously in HeLa cells. The activity of the peptide transporters was assessed by measuring the uptake of radiolabeled glycylsarcosine in the presence of a H+ gradient. Valacyclovir inhibited the uptake of glycylsarcosine with an inhibition constant (Ki) of 0.49 +/- 0.04 mM in Caco-2 cells and 0.17 +/- 0.01 mM in SKPT cells. In both cell types, the inhibition was competitive. Acyclovir, in contrast to valacyclovir, did not interact with the peptide transporters. Similar results were obtained with heterologously expressed human PEPT1 and rat PEPT2. Valacyclovir inhibited the hPEPT1-mediated glycylsarcosine transport competitively with a Ki value of 0.74 +/- 0.14 mM. The rPEPT2-mediated transport of glycylsarcosine was also inhibited by valacyclovir competitively and the Ki value for the process was 0.39 +/- 0.03 mM. Acyclovir did not interact with either of these cloned peptide transporters. We conclude that valacyclovir is a substrate for the peptide transporters PEPT1 and PEPT2 and that a peptide bond is not a prerequisite for recognition as a substrate by the peptide transporters.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610386     DOI: 10.1006/bbrc.1998.8628

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  68 in total

Review 1.  Intestinal peptide transport systems and oral drug availability.

Authors:  C Y Yang; A H Dantzig; C Pidgeon
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

Review 2.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

3.  Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.

Authors:  Dana D Phan; Peter Chin-Hong; Emil T Lin; Pascale Anderle; Wolfgang Sadee; B Joseph Guglielmo
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 4.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 5.  Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin.

Authors:  Haiqi Chen; Dolores D Mruk; Weiliang Xia; Michele Bonanomi; Bruno Silvestrini; Chuen-Yan Cheng
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1.

Authors:  Monica Sala-Rabanal; Donald D F Loo; Bruce A Hirayama; Eric Turk; Ernest M Wright
Journal:  J Physiol       Date:  2006-04-20       Impact factor: 5.182

7.  Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice.

Authors:  Yuqing Wang; Yongjun Hu; Ping Li; Yayun Weng; Nobuhiko Kamada; Huidi Jiang; David E Smith
Journal:  Biochem Pharmacol       Date:  2018-01-03       Impact factor: 5.858

8.  Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide.

Authors:  Shu-Pei Wu; David E Smith
Journal:  Mol Pharm       Date:  2013-01-07       Impact factor: 4.939

9.  Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme.

Authors:  Ulrika Tehler; Cara H Nelson; Larryn W Peterson; Chester J Provoda; John M Hilfinger; Kyung-Dall Lee; Charles E McKenna; Gordon L Amidon
Journal:  Antiviral Res       Date:  2009-12-05       Impact factor: 5.970

10.  Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters.

Authors:  Dilara Jappar; Yongjun Hu; Richard F Keep; David E Smith
Journal:  Pharm Res       Date:  2008-09-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.